Sarcoma News

New data revealed that 48% of patients who received chimeric antigen receptor T-cell therapy for cancer treatment experienced neurological toxicity, according to a retrospective review published in Brain.

CHICAGO — Patients with various subtypes of pretreated, metastatic sarcoma showed improved response rates and survival when treated on genomically matched phase 1 trials, according to study results presented at ASCO Annual Meeting.

Non-Latino white adolescents and young adults who are cancer survivors have a lower risk for subsequent death compared with survivors of other races and ethnicities, according to research published in JNCI Cancer Spectrum.

CHICAGO — Lewis H. Bender, MS, MA, MBA, founder, president and CEO of Intensity Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about preliminary results of the company’s ongoing phase 1/phase 2 trial of its lead product candidate.

Here we are, back from another bigger, better, more extreme ASCO Annual Meeting.

About one in three cancer survivors, representing nearly 5.4 million people in the United States, reported experiencing chronic pain, with one in six survivors enduring high-impact chronic pain that limits life or work activities, according to a research letter published in JAMA Oncology. “Chronic pain is one of the most common long-term effects of cancer treatment and has been linked with an impaired quality of life, lower adherence to treatment, and higher health care costs,” Changchuan Jiang, MD, MPH, resident in internal medicine at Mount Sinai Hospital, and colleagues wrote. “Nevertheless, there is a paucity of information regarding the prevalence of, and risk factors for, the development of chronic pain among cancer survivors.”

CHICAGO — Maura Dickler, MD, vice president of late-phase oncology development at Eli Lilly, spoke with HemOnc Today about key data presented at ASCO Annual Meeting.

The FDA granted fast track designation to TRQ-1501, a deep-primed IL-15 T-cell immunotherapy for the treatment of relapsed or refractory solid tumors and lymphomas that express any of five tumor-associated antigens, according to the agent’s manufacturer.

CHICAGO — Patients with anti-PD-1-naive triple-negative breast cancer and PD-1-relapsed or refractory melanoma demonstrated antitumor benefit from MIW815 plus spartalizumab, according to results of a phase 1b study presented at ASCO Annual Meeting.

CHICAGO — Rafael Amado, MD, president of research and development for Adaptimmune, spoke with HemOnc Today at ASCO Annual Meeting about the company’s efforts to use T-cell therapy to treat cancer.